Tislelizumab for lung cancer with brain metastases
Part of Cancer clinical trials.
This trial tests a drug called tislelizumab for people with advanced lung adenocarcinoma that has spread to the brain but is not causing symptoms. It is for those who have not had prior treatment and whose tumors do not have certain gene changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV lung adenocarcinoma that cannot be removed with surgery or radiation
- You have brain metastases that are not causing symptoms
- You have not received any treatment for advanced lung cancer before
- Your overall health status is good (ECOG score 0 or 1)
- You have at least one measurable tumor outside the skull
- Your life expectancy is more than 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of tislelizumab (a type of immunotherapy) with chemotherapy, with or without radiation, for people with small cell lung cancer that has spread to only a few places in the body. The goal is to see if this combination helps control the cancer better.
This study tests a combination of three treatments—an immunotherapy drug called tislelizumab, chemotherapy, and a procedure called BACE—for advanced lung cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This trial tests if adding the immunotherapy drug Tislelizumab to standard chemotherapy can shrink stage III non-small cell lung cancer that cannot be surgically removed at first. The goal is to see if this combination makes the cancer small enough for surgery.
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
This trial tests whether adding platinum-based chemotherapy to the immunotherapy drug tislelizumab helps people with advanced non-small cell lung cancer that has high PD-L1 levels and at least one large tumor. It is for people who have not had treatment before and cannot have curative surgery or radiation.
Hear when a new Lung Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.